Regen BioPharma (RGBPP) Invested Capital (2016 - 2025)
Regen BioPharma (RGBPP) has disclosed Invested Capital for 13 consecutive years, with -$6.6 million as the latest value for Q4 2025.
- On a quarterly basis, Invested Capital fell 15.74% to -$6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.6 million, a 15.74% decrease, with the full-year FY2025 number at -$6.3 million, down 20.39% from a year prior.
- Invested Capital was -$6.6 million for Q4 2025 at Regen BioPharma, down from -$6.3 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of -$4.4 million in Q2 2024 to a low of -$76.7 million in Q1 2022.
- A 5-year average of -$10.5 million and a median of -$5.8 million in 2025 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: crashed 2982.17% in 2021, then soared 93.71% in 2023.
- Regen BioPharma's Invested Capital stood at -$8.3 million in 2021, then surged by 41.19% to -$4.9 million in 2022, then grew by 9.06% to -$4.4 million in 2023, then fell by 27.86% to -$5.7 million in 2024, then fell by 15.74% to -$6.6 million in 2025.
- Per Business Quant, the three most recent readings for RGBPP's Invested Capital are -$6.6 million (Q4 2025), -$6.3 million (Q3 2025), and -$5.8 million (Q2 2025).